Company intelligence / Profile preview

NanoRay Biotech

Ownership: Private
Employees: ~45
Development stage: Other

Overview

NanoRay’s lead oncology program, Auger Molecular Therapy (AMT), received IND approval from both the US FDA and Taiwan FDA in 2022. The first-in-human Phase 1 trial is scheduled to begin at Taipei Medical University Hospital. Their RevoluX hand diagnostic radiology system has been approved by the USFDA and TFDA for clinical use in bone age, bone density, and gout detection.

Therapeutic areas: RheumatologyEndocrinologyOncology
Modalities: DeviceSmall molecule (IUdR, as part of Auger Molecular Therapy)Radiotherapy-based therapy (Auger effect via monochromatic X-ray)
Industry: Biotech

Drug pipeline

1 asset

Auger Molecular Therapy

Unknown

Partnerships

BioDuro-Sundia – CRDMO partner supporting dosage form development, API production & clinical trial materials manufacturing for AMT program

Beyond the preview

Go deeper on NanoRay Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoRay Biotech.

Explore the full profile